Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Trial Profile

A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Granulocyte macrophage colony stimulating factor (Primary) ; TG 01 Targovax (Primary) ; Dexamethasone
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Targovax
  • Most Recent Events

    • 09 Jul 2020 This trial is discontinued in Spain, according to European Clinical Trials Database record.
    • 17 Feb 2020 Results assessing the safety and efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma, published in the British Journal of Cancer
    • 23 May 2019 According to a Targovax ASA media release, this three-year survival data finalizes the data collection and the trial is now considered complete. The completed data will be presented and published later this year.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top